On the 16th, Alteogen is surging 4% intraday. It is analyzed as being due to President Jeon Tae-yeon of Alteogen signaling a large-scale technology transfer at the JP Morgan Health Conference (JPMHC 2026).
As of 12:34 p.m. that day, on the KOSDAQ market, Alteogen is trading at 493,500 won, up 23,000 won (4.89%) from the previous trading day. Alteogen opened at 470,500 won that day and, after widening its intraday losses and slipping to the 460,000-won level, reversed higher intraday as news of the technology transfer spread.
On the 15th (local time) at JPMHC 2026 in San Francisco, United States, President Jeon said, "We plan to make an announcement on the technology transfer for ALT-B4 as early as next week," and noted, "It is expected to be similar in size to the previous transfer." Considering past technology transfer cases, the market notes that the contract size could reach from several hundred billion won to the trillion-won range.
ALT-B4 is a recombinant enzyme protein that temporarily breaks down hyaluronic acid under the skin, and it was developed based on Alteogen's platform technology "Hybrozyme." Applying ALT-B4 allows drugs in existing intravenous (IV) formulations to be administered subcutaneously (SC). From the perspective of global pharmaceutical companies, there is an advantage in that they can increase dosing convenience through a formulation change while extending the patent term.
That day, President Jeon also expressed a position on the patent dispute. Jeon said, "Functionally, ALT-B4 is the same as existing competing enzymes, but from a patent perspective, it is a completely different molecule," and added, "Although the market focuses on the legal dispute with Halozyme, mentions related to the patent dispute rarely come up in meetings with global corporations," conveying the view that the impact of the patent dispute would be limited.